Medico Remedies
: MEDICO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Medico Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medico Remedies Ltd is a pharmaceutical formulation manufacturing and marketing company established in 1994. The company produces a diverse range of therapeutic drugs, including antibiotics, anti-infectives, antimalarials, and various chronic care medications.
Business Model
The company generates revenue through the manufacturing and sale of a broad portfolio of pharmaceutical formulations across multiple therapeutic segments. It serves both domestic and potentially international markets by providing essential medicines in various dosage forms.
Growth Outlook
Growth is expected to be driven by the expansion of its diverse therapeutic product portfolio and the continued demand for essential pharmaceutical formulations. The company leverages its manufacturing capabilities to address a wide spectrum of health conditions.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and regulatory inspections by health authorities.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins.
- Raw Material Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) can adversely affect production costs and financial performance.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, leading to intense price competition from both large players and smaller generic manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Medico Remedies and 5,000+ companies — free.
Key Metrics
REVENUE
₹206 Cr
TTM · standalone
NET PROFIT
₹13 Cr
TTM · standalone
EPS
₹1.59
TTM · standalone
RETURN ON EQUITY
20.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
30.1%
TTM · standalone
P/E
24.4x
Q4 FY26 · standalone
EV/EBITDA
13.7x
Q4 FY26 · standalone
EBITDA MARGIN
11.1%
TTM · standalone
NET PROFIT MARGIN
10.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2%
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Medico RemediesMEDICO | ₹352 Cr | 26.67 | 16.07 | 36.7% | 11.1% | 20.0% | 30.1% | +10.9% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Medico Remedies
: MEDICO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Medico Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medico Remedies Ltd is a pharmaceutical formulation manufacturing and marketing company established in 1994. The company produces a diverse range of therapeutic drugs, including antibiotics, anti-infectives, antimalarials, and various chronic care medications.
Business Model
The company generates revenue through the manufacturing and sale of a broad portfolio of pharmaceutical formulations across multiple therapeutic segments. It serves both domestic and potentially international markets by providing essential medicines in various dosage forms.
Growth Outlook
Growth is expected to be driven by the expansion of its diverse therapeutic product portfolio and the continued demand for essential pharmaceutical formulations. The company leverages its manufacturing capabilities to address a wide spectrum of health conditions.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and regulatory inspections by health authorities.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins.
- Raw Material Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) can adversely affect production costs and financial performance.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, leading to intense price competition from both large players and smaller generic manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Medico Remedies and 5,000+ companies — free.
Key Metrics
REVENUE
₹206 Cr
TTM · standalone
NET PROFIT
₹13 Cr
TTM · standalone
EPS
₹1.59
TTM · standalone
RETURN ON EQUITY
20.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
30.1%
TTM · standalone
P/E
24.4x
Q4 FY26 · standalone
EV/EBITDA
13.7x
Q4 FY26 · standalone
EBITDA MARGIN
11.1%
TTM · standalone
NET PROFIT MARGIN
10.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.2%
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26